Quantitative Imaging of Cancer Drug Resistance via Radioluminescence Microarrays
Quantitative Imaging of Cancer Drug Resistance via Radioluminescence Microarrays
批准号:
8674402
负责人:
Guillem Pratx
金额:
$36.31万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-01 至 2019-04-30
关键词:
Antineoplastic AgentsApoptosisAutoradiographyBehaviorBiochemicalBiochemistryCalibrationCell CountCell CycleCell FractionCell LineCellsCellular StressComputer softwareComputersCoupledDetectionDevicesDiseaseDrug EffluxDrug KineticsDrug resistanceEnvironmentEventFluorescenceFluorescence MicroscopyFluorouracilGoalsHeterogeneityImageImage AnalysisImaging DeviceImaging TechniquesIndividualLabelLeadLifeLocationMalignant NeoplasmsMasksMeasurementMeasuresMethodsMicroscopeMicroscopyMolecularMonitorOrganismPatternPharmaceutical PreparationsPlayPopulationPopulation HeterogeneityPositioning AttributePositron-Emission TomographyPreparationProceduresProcessPropertyRadiationRadioactiveRadioisotopesRadiolabeledRadionuclide ImagingResearchResistanceResolutionRoleSamplingScintillation CountingStem cellsTechniquesTechnologyTimebasecancer cellcancer typecell typechemotherapeutic agentchemotherapydata acquisitiondesigneffective therapyhigh throughput screeningimaging modalityimprovedinfancyinstrumentinterestirinotecannovelpublic health relevanceradiotracerresistance mechanismresponsesingle cell analysissmall moleculesoftware developmentstemtooltraffickingtumortumorigenicuptakeuser-friendly
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): It is becoming increasingly apparent that cell populations are heterogeneous in their functions, disease states and response to therapy. Tumor heterogeneity is one of the main factors contributing to acquire drug resistance. Substantial interest is now devoted to characterization methods that operate at the single-cell level, as opposed to bulk analyses that can only measure average properties over a given population. Fluorescence methods have long been used to measure molecular processes in single living cells. However, a vast number of small molecules remain invisible to fluorescence probing. These molecules lack inherent fluorescence and cannot be fluorescently labeled without altering their biochemical activity. Precise and sensitive quantitation of small molecules (e.g. in drug pharmacokinetics studies) remains the domain of radionuclide detection methods (scintillation counting, autoradiography, and positron emission tomography) since radiolabeling in most cases can preserve biochemical activity. The recent finding that radionuclide molecules too can be imaged at the cellular level in a microscope represents a radical departure from what was previously known. This new method, called radioluminescence microscopy, can measure the accumulation of a radionuclide molecule in single living cells. While the technique has been demonstrated for a variety of applications, the technology is still in its infancy. In this proposa, we are proposing several radical improvements that will allow us to measure radionuclide probe uptake in up to 1000 individual cells, in a single acquisition. Studies that investigate large cell
numbers are necessary for statistical reasons and due to the existence of rare cell subpopulations. Based on encouraging preliminary results, we are proposing a new instrument design called the radioluminescence microarray that can achieve this goal. This new design incorporates several radical improvements that will transform radioluminescence microscopy into a versatile tool for high-throughput studies with many potential applications. In Aim 1, we will develop a new device called the radioluminescence microarray. This device includes a micrometer-thin scintillator for high-resolution imaging, a microwell array for optimized cell placement, a fluidics platform for repeatable sample preparation, and an improved epifluorescence add-on for multi-modality imaging. In Aim 2, we will implement software for real-time display and automated analysis of radioluminescence microscopy images. Last, in Aim 3, we will validate the overall approach by investigating the interaction with single living cells of -fluorouracil (5-FU), a small-molecule non-fluorescent chemotherapeutic agent. Using the radioactive form of the drug ([18F] 5-FU), we will determine how 5FU distributes in heterogeneous cancer cell populations. Fluorescence microscopy will be used to assign cells to different subpopulations according to factors such as position in the cell cycle or stem-cell status. In summary, this project will develop new a new instrument with unmatched capabilities, which will be applied to deepening our understanding of drug resistance in heterogeneous cancer cell populations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigation of nanobubble nucleation by radiation therapy
-
批准号:10642367
-
项目类别:
-
资助金额:$19.33万
-
财政年份:2023
-
负责人:Guillem Pratx
-
依托单位:
Preclinical microphysiological tumor models for nuclear medicine
-
批准号:10587674
-
项目类别:
-
资助金额:$52.99万
-
财政年份:2023
-
负责人:Guillem Pratx
-
依托单位:
A Novel Assay to Individualize Resensitization of Iodine-Refractory Thyroid Cancer
-
批准号:10612661
-
项目类别:
-
资助金额:$21.69万
-
财政年份:2023
-
负责人:Guillem Pratx
-
依托单位:
New tools for tracking single cells in vivo
-
批准号:10400200
-
项目类别:
-
资助金额:$58.9万
-
财政年份:2020
-
负责人:Guillem Pratx
-
依托单位:
New tools for tracking single cells in vivo
-
批准号:10055061
-
项目类别:
-
资助金额:$65.0万
-
财政年份:2020
-
负责人:Guillem Pratx
-
依托单位:
New tools for tracking single cells in vivo
-
批准号:10248540
-
项目类别:
-
资助金额:$62.01万
-
财政年份:2020
-
负责人:Guillem Pratx
-
依托单位:
Tumor-targeted delivery and cell internalization of theranostic gadolinium nanoparticles for image-guided nanoparticle-enhanced radiation therapy
-
批准号:10457237
-
项目类别:
-
资助金额:$18.11万
-
财政年份:2019
-
负责人:Guillem Pratx
-
依托单位:
High-throughput radionuclide counting and sorting of single cells
-
批准号:8850698
-
项目类别:
-
资助金额:$24.44万
-
财政年份:2015
-
负责人:Guillem Pratx
-
依托单位:
Real-time tracking of single cells in live animals
-
批准号:8930185
-
项目类别:
-
资助金额:$24.09万
-
财政年份:2014
-
负责人:Guillem Pratx
-
依托单位:
Quantitative Imaging of Cancer Drug Resistance via Radioluminescence Microarrays
-
批准号:9477626
-
项目类别:
-
资助金额:$33.34万
-
财政年份:2014
-
负责人:Guillem Pratx
-
依托单位:
Real-time tracking of single cells in live animals
-
批准号:8828429
-
项目类别:
-
资助金额:$20.08万
-
财政年份:2014
-
负责人:Guillem Pratx
-
依托单位:
Quantitative Imaging of Cancer Drug Resistance via Radioluminescence Microarrays
-
批准号:9267135
-
项目类别:
-
资助金额:$33.34万
-
财政年份:2014
-
负责人:Guillem Pratx
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: